Peer-influenced content. Sources you trust. No registration required. This is HCN.
Annals of Internal Medicine
In an adaptive randomized trial of adults with long COVID, fluvoxamine modestly reduced fatigue and improved quality-of-life scores through 90 days, while metformin findings remained inconclusive after dose modification and early termination.
Family Medicine/General Practice October 16th 2026
Annals of Clinical and Translational Neurology (ACTN)
In a specialty-clinic cohort of 2,329 adults with Neuro-PASC, females reported more neurologic symptoms, greater fatigue, and, among nonhospitalized patients, poorer attention than males approximately 16 months after symptom onset.
Infectious Diseases September 28th 2026
MDLinx
Fluvoxamine reduced fatigue and improved quality-of-life measures in adults with long COVID in a randomized placebo-controlled trial. The findings provide evidence for a potential therapy, although further research is needed to define optimal patient selection and treatment strategies.
Infectious Diseases July 31st 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS